+
Site Tour
CONGENITAL
HEART DEFECTS

SWITCH TO THE interventional VIEW    For more information specific to interventional cardiology regarding PDA closure

AMPLATZER PICCOLO™ OCCLUDER:
PROVEN SAFETY FOR THE YOUNGEST INFANTS AND UP

The safety and efficacy of the Amplatzer Piccolo™ Occluder in patients weighing ≥ 700 grams was studied in a 50-patient pivotal trial and in 150 additional patients under a continued access protocol. When combined, the study enrolled a total of 200 patients. At the time of the procedure, 100 patients weighed ≤ 2 kg and the other 100 patients weighed >2 kg.1

AVERAGE
IMPLANT SUCCESS

99.0% for patients ≤ 2kg
92.0% for patients > 2kg

EFFECTIVE
PDA CLOSURE*

100% for patients ≤ 2kg
98.8% for patients > 2kg

6-MONTH
SURVIVAL

Overall survival for the IDE and CAP patients at 6 months
96.0% for patients ≤ 2kg
98.0% for patients > 2kg

MAJOR
COMPLICATIONS†

Through 180 days
4.2% for patients ≤ 2kg
0% for patients > 2kg

CAP=continued access protocol, IDE=investigational device exemption.
*Assessed by echocardiography and defined as the presence of either a grade 0 (none) or grade 1 (trivial) shunt.
†Major complications were defined as device or procedure-related adverse events resulting in death, a life-threatening adverse event, persistent or significant disability and/or surgical intervention.

FIND OUT MORE ABOUT

PICCOLO™ CLINICAL TRIAL SUMMARY

PICCOLO 3-YEAR FOLLOW-UP DATA

AVERAGE
IMPLANT SUCCESS

99.0% for patients ≤ 2kg
92.0% for patients > 2kg

EFFECTIVE
PDA CLOSURE*

At 3-year follow-up Only IDE patients included a 3 year echo

6-MONTH SURVIVAL

Overall survival for the IDE and
CAP patients at 6 months
96.0% for patients ≤ 2kg
98.0% for patients > 2kg

MAJOR COMPLICATIONS†

Through 180 days
4.2% for patients ≤ 2kg
0% for patients > 2kg

IDE=investigational device exemption
*Assessed by echocardiography and defined as the presence of either a grade 0 (none) or grade 1 (trivial) shunt.
†Major complications were defined as device or procedure-related adverse events resulting in death, a life-threatening adverse event, persistent or significant disability and/or surgical intervention.

INTERVENTIONAL DEVICE EXEMPTION AND PICCOLO CLINICAL TRIAL RESULTS

LEARN MORE

Connext
Hub

Learn emerging and established information on cardiovascular conditions and stroke prevention technologies.

Find out more

References
  1. Sathanandam SK, Gutfinger D, O’Brien L et al. Amplatzer Piccolo Occluder clinical trial for percutaneous closure of the patent ductus arteriosus in patients ≥700 grams. Catheter Cardiovasc Interv. 2020;96(6):1266–1276. doi.org/10.1002/ccd.28973.
  2. Zahn E. The Amplatzer Piccolo™ (ADOIIAS) U.S. Clinical Trial 3-Year Follow-up Report. Presented at: CSI Frankfurt; June 22-25, 2022

© Abbott 2023. All rights reserved. 9-EH-5-14534-01 09-2023

You are about to leave my-connext.com

You are now leaving my-connext.com. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.

The content on this website is intended for healthcare professionals in EMEA with applicable health authority product registrations, excepted those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Click OK to confirm you are a healthcare professional to proceed.

OK Decline